Joris Van De Haar
Amsterdam, NH 1066CX, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Journal: Nature medicine
Published: March 06, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 12, 2024
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Journal: Scientific reports
Published: February 09, 2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 05, 2024
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 23, 2023
The synthetic lethal interaction between CDS1 and CDS2 is a vulnerability in uveal melanoma and across multiple tumor types.
Journal: Nature genetics
Published: November 28, 2023
Third-Line Therapy in Metastatic Colorectal Cancer.
Journal: The New England journal of medicine
Published: July 12, 2023
Functional precision oncology using patient-derived assays: bridging genotype and phenotype.
Journal: Nature reviews. Clinical oncology
Published: February 20, 2023
Last Updated: 09/26/2026